"It's hard to calculate Zenith's valuation because it generates no revenue and profits"

Correct if I'm wrong koo - did these other biotechs have sales or profits?

Also I believe some of them were a lot further off from even seeing the "corner"?

& aren't some of Zenith trials wrapping  in this quarter/within the next 3 months? Rounding the corner?

surley some valuation can be considered based on other biotech's that have been bought out at even early stages etc etc?